(7CI,8CI,9CI)-6-甲基-噻吩并[3,2-b]吡啶 | 28988-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: (7CI,8CI,9CI)-6-甲基-噻吩并[3,2-b]吡啶
• 英文名称: 6-Methyl-thieno<3,2-c>pyridin
• 英文别名: 6-Methylthieno[3,2-c]pyridine
• CAS: 28988-26-3
• 化学式: C₈H₇NS
• 分子量: 149.216
• InChiKey: LGLICFZQNLVOLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 吡啶 、 copper oxide-chromium oxide 、 甲烷 作用下， 生成 (7CI,8CI,9CI)-6-甲基-噻吩并[3,2-b]吡啶
  参考文献：
  名称：

  Catalytic Synthesis of Heterocycles. IX.¹ Dehydrocyclization of 2-Methyl-5-ethyl-4-pyridinethiol to 6-Methyl-5-azathianaphthene

  摘要：

  DOI：

  10.1021/jo01359a021

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
  申请人：Malecha James W.

  公开号：US20070270434A1

  公开（公告）日：2007-11-22

  The present invention relates to compounds and methods useful as inhibitors of PPAR, particularly PPARδ, and for the treatment or prevention of PPAR-mediated diseases, including metabolic diseases.

  本发明涉及化合物和方法，可用作PPAR抑制剂，特别是PPARδ的抑制剂，并用于治疗或预防PPAR介导的疾病，包括代谢性疾病。
• Process for the preparation of thieno(3,2-c) pyridine and derivatives
  申请人：Parcor

  公开号：US04065459A1

  公开（公告）日：1977-12-27

  This invention relates to a process for the preparation of compounds having the formula: ##STR1## in which R.sub.1 is H or lower alkyl and R.sub.2 is H or lower alkyl, or phenyl or benzyl optionally substituted with at least one halogen or a lower alkyl, lower alkoxy, trifluoromethyl or nitro group. According to this method, a compound of the formula: ##STR2## in which R.sub.1 and R.sub.2 are as defined above and R.sub.3 is H or optionally substituted alkyl or benzyl, is reacted with a derivative Hal--SO.sub.2 --R (III) in which Hal is halogen and R is optionally substituted alkyl, aryl or aralkyl, to give a derivative of the formula: ##STR3## in which the various symbols have the above-defined meanings, and the sulfonated derivative of the formula (IV) is heated in the presence of an acid, to give the compound of the formula (I).

  本发明涉及一种制备具有以下式子的化合物的方法： ##STR1## 其中R.sub.1为H或低碳基，R.sub.2为H或低碳基，或苯基或苄基，可选地带有至少一个卤素或低碳基，低烷氧基，三氟甲基或硝基基团。根据这种方法，将具有以下式子的化合物： ##STR2## 其中R.sub.1和R.sub.2如上所定义，R.sub.3为H或可选地取代的烷基或苄基，与衍生物Hal--SO.sub.2--R(III)反应，其中Hal为卤素，R为可选地取代的烷基，芳基或芳基烷基，以给出以下式子的衍生物： ##STR3## 其中各符号具有上述定义，式子(IV)的磺化衍生物在酸的存在下加热，以给出式子(I)的化合物。
• Useful indole compounds
  申请人：Bartolini Wilmin

  公开号：US20070203209A1

  公开（公告）日：2007-08-30

  Indoles having various activities, including indoles that are CRTH2 are described. The compounds are useful for treating asthma, neuropathic pain, allegic rhinitis and other disorders.

  本文描述了具有多种活性的吲哚类化合物，包括CRTH2的吲哚类化合物。这些化合物可用于治疗哮喘、神经病性疼痛、过敏性鼻炎和其他疾病。
• Pyrimidine derivatives
  申请人：Sato Michitaka

  公开号：US20070197551A1

  公开（公告）日：2007-08-23

  This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.

  本发明提供了由下式表示的嘧啶衍生物，其中，环A代表碳环基团或杂环基团，X1代表氢、低碳基、氨基等，X2代表氢或低碳基，Y代表直接键或硫或氮，n代表0-4的整数，Ar代表以下式的基团，或其盐，同时表现出5-HT1A激动活性和5-HT3拮抗活性，并且对治疗诸如肠易激综合征等疾病有用。本发明进一步提供了一种IBS治疗方法，其特征在于在体内同时和协同地发挥5-HT1A激动活性和5-HT3拮抗活性，包括给予同时表现出5-HT1A激动活性和5-HT3拮抗活性的5-HT3拮抗剂，或同时给予5-HT1A激动剂和5-HT3拮抗剂，按顺序或间隔给予。